The American Academy of Ophthalmology reported (June 2021) a shortage of bevacizumab as used off-label, aliquoted, for ophthalmic indications in the U.S. The issue surrounding off-label and compounding pharmacy use, particularly with this class of products, were discussed in a recent editorial by Dr. Novack and UC Davis colleague, Ala Moshiri MD, Ph.D. in an article in the American Journal of Ophthalmology. Such use is at risk for many reasons – including availability.
Recent Posts
- 60 products!
- PharmaLogic to provide service to Zhaoke Ophthalmology
- Value of medical writers discussed in top journal
- Client publishes 100th paper – PharmaLogic wrote the first one
- Dr. Novack’s paper among top 100 glaucoma papers
- Unintended consequences of off-label use
- Off-label use: Article in the American Journal of Ophthalmology
Gary D. Novack, PhD, president of PharmaLogic Development
Dr. Novack speaking at ASCRS 2014
Dr. Novack talked in two symposia at the Glaucoma 360 event of the Glaucoma Research Foundation in San Francisco.
PharmaLogic sponsor a northern California bicycle riding team “Caballo Rojo
UCSC Chancellor George Blumenthal and Foundation President Ken Doctor thank Dr. Novack for his service to UCSC.
Dr. Novack on floor of California State Assembly with Assemblymember Beall (D-San Jose)
Dr. Novack addresses European Glaucoma Society on Generic Drugs
Dr. Novack with Dr. Wiley Chambers (FDA/CDER), Dr. Ellen Strahlman (CMO GSK), and Dr. Malvina Eydelman (FDA/CDRH) at the Glaucoma 360 event.
Dr. Novack speaking at International Symposium on Ocular Pharmacology and Therapeutics, Vienna, Austria
Dr. Elizabeth Moyer and Dr. Novack at ophthalmology workshop European Medicines Agency
Dr. Novack presents young investigator award at ASPET to Stephanie Piecewicz of MIT